Research graph
References from Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. Local targets link to admitted publications; unresolved targets remain external evidence.
Myelodysplastic syndromes
2020 · External reference
The genetic basis of myelodysplasia and its clinical relevance
10.1182/blood-2013-09-381665 · 2013 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
Efficacy of lenalidomide in myelodysplastic syndromes
2005 · External reference
International Scoring System for evaluating prognosis in myelodysplastic syndromes
10.1182/blood.v89.6.2079 · 1997 · External reference
Revised International Prognostic Scoring System for myelodysplastic syndromes
10.1182/blood-2012-03-420489 · 2012 · External reference
Molecular International Prognostic Scoring System for myelodysplastic syndromes
10.1056/evidoa2200008 · 2022 · External reference
Unresolved reference
2020 · External reference
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
10.1182/blood.2021014472 · 2022 · External reference
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
10.1182/blood-2005-10-4149 · 2006 · External reference
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the International Prognostic Scoring System
10.1200/jco.2010.28.3978 · 2011 · External reference
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
10.1200/jco.2011.35.6394 · 2012 · External reference
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
10.1182/blood-2007-03-082404 · 2007 · External reference
Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes
10.1002/ajh.25287 · 2018 · External reference
Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome
10.1016/j.leukres.2011.01.003 · 2011 · External reference
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
10.1038/leu.2010.231 · 2011 · External reference
Prognostication in myelodysplastic syndromes (neoplasms): molecular risk stratification finally coming of age
10.1016/j.blre.2022.101033 · 2022 · External reference
Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes
10.1182/blood.2022018896 · 2023 · External reference
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria
2023 · External reference
Assessment and validation of the Molecular International Prognostic Scoring System for myelodysplastic syndromes
10.1038/s41375-023-01910-3 · 2023 · External reference
